.
In recent years, Japan has undergone regulatory reform. One of the driving forces behind these changes has been the country's rising costs of health care [4] . Ward and Piccolo summarized the current situation by noting that, "[l]ike most industrialized countries, Japan is faced with a rapidly aging population and a declining birthrate" [5] . In 2005, people aged у65 years represented 19.9% of Japan's population; however, this segment is predicted to increase to 26.0% by 2015 [6] . The increase in elderly persons combined with Japan's stagnant and slow economic growth are creating a financial crisis for the country's health care system [5] .
Government deregulation of some OTC drugs has been used as a means to reduce health care costs. Some of the OTC drugs with well-established safety records have been reclassified as the category of "quasi-drugs" or as functional foods. These products are no longer limited to being sold at drug stores and pharmacies but can be sold anywhere, including convenience stores, grocery stores, and kiosks at train stations, without a pharmacist's supervision. The category of drugs for gastrointestinal health is one that was deregulated [7] . Biofermin S (Biofermin Pharmaceutical), which contains live Bifidobacterium bifidum, Streptococcus faecalis, and L. acidophilus, is one popular product for treatment of diarrhea. It was transferred to the quasi-drug (lyaku-bugaihin) category, which represents products with mild effects on the body.
Japan is also encouraging the public to adopt healthier lifestyles as another means to reduce spending for health care [8] .
Measures include the implementation of antismoking campaigns, the promotion of self-medication, and the use of health foods to prevent or reduce the risk of disease.
Japan's regulatory classification system is shown in figure 1  [2] . Health foods, represented by the category "foods with health claims" (which includes the categories FOSHU and foods with nutrient claims) must undergo approval based on the Nutrition Improvement Act (section 12-1). These products contain ingredients that influence physiological functions of the body and can be used to maintain health and/or to achieve specific health effects. For example, some probiotic foods claim to maintain gastrointestinal health.
Probiotics are used today in many major Japanese hospitals to treat gastrointestinal disorders, such as diarrhea and constipation, and symptoms related to antibiotic use. An example of one such product, marketed by Wakanuga, contains 3 strains: L. acidophilus KS-13, B. bifidum G9-1, and B. longum MM-2 [9, 10]. These strains are sold as a prescription drug, an OTC drug, and a quasi-drug. To support the marketing of this product in all these categories, the following information was determined: efficacy [11] [12] [13] [14] , stability [15] (Food Products Laboratory, Portland, Oregon, personal communication), resistance to stomach acids [12, 16, 17] (Food Products Laboratory, Portland, Oregon, personal communication), implantation (colonization) [18] , adherence to the gastrointestinal tract [19] , and in vivo distribution and recovery [20] .
Health targets for probiotic FOSHU marketed in Japan include gastrointestinal conditions, immunity, allergy, cold and influenza-like symptoms, cholesterol levels, blood pressure levels, and diabetes. Recent correspondence with Japanese authorities highlights the current and future directions for probiotics in Japan (Japanese Regulatory Authority, personal communication):
1. Probiotics (lactic acid-producing bacteria) are used as medicines and can be used as foods without medicinal claims.
2. As foods, probiotics have no specific restrictions. However, fermented milk or lactic acid drinks are required to have a lower limit of lactic acid bacteria.
3. If probiotics are marketed as foods, efficacy claims are prohibited on the labeling. To make claims about efficacy, one must obtain special permission from the Ministry of Health and Welfare for the product to be considered FOSHU, for which substantiation of efficacy and safety is mandatory.
4. Good manufacturing practices are required for drugs but not for foods.
On the basis of the Japanese experience, there are issues that the United States will need to address with regard to probiotics. Good manufacturing practices, including regulatory audits, should be required for probiotics. Testing should address stability and cell viability, which are important not only for shelflife determination but also for efficacy. Cell viability is determined during stability testing, and numbers of viable cells should be included on the label, reflecting the numbers at the time of consumption, not at the time of manufacture. Because probiotics exert their effects through the secretion of substances such as vitamins and bateriocins, viable-cell counts reflect this capacity. The source of the cell line is also important. It may affect how the strain implants in the luminal epithelial cells of the human intestinal tract, which can, in turn, influence the probiotic efficacy. Efficacy should be presented in scientific publications.
To date, Japan has been the global market leader in probiotics. Although safety considerations remain a concern of the US medical and scientific communities, most probiotics sold today as FOSHU in Japan and as foods or dietary supplements in the United States and Europe have a long history of safe use. With more education about probiotics, in conjunction with new scientific findings and changing consumer demands and social attitudes, the US market, currently estimated at $700 million, is poised to expand [21] .
